Open an account

Arbutus Biopharma

ABUS · NASDAQ

$4.33+$0.10 (+2.36%)TodayMarket closed ·
Prev close $4.23

About ABUS

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, British Columbia and currently employs 19 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Employees
19
Headquarters
Warminster, British Columbia
Listed
Nov 13, 2010
Sector
Health Care
Industry
Biotechnology
Website
arbutusbio.com

ABUS key statistics

Market cap
857.80M
Price-earnings ratio
5.35
Dividend yield
—
Average volume
7.64M
Volume
2.11M
Open price
$4.24
High today
$4.37
Low today
$4.22
52 Week high
$5.45
52 Week low
$3.50

Arbutus Biopharma (ABUS) at a glance

Arbutus Biopharma (ABUS) last traded at $4.33, with a market cap of 857.80M and a price-to-earnings ratio of 5.35.

Today the stock has traded between $4.22 and $4.37. The current price is 2.6% above the day's low and 0.8% below its high.

Volume so far is 2.11M shares, below the average of 7.64M shares a day.

Over the past year Arbutus Biopharma has ranged from $3.50 to $5.45, and now sits 43% of the way up that range.

Arbutus Biopharma met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.03 per share against an estimate of -$0.0204.

The average analyst price target is $5.61, 29.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $5.61
Low
$5.55
Now
$4.33
High
$5.78

ABUS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 46.4% on average.

  1. Q3 FY24: reported -$0.09 per share against an estimate of -$0.0965
  2. Q4 FY24: reported -$0.07 per share against an estimate of -$0.0816
  3. Q1 FY25: reported -$0.13 per share against an estimate of -$0.1055
  4. Q2 FY25: reported $0.01 per share against an estimate of -$0.0485
  5. Q3 FY25: reported -$0.04 per share against an estimate of -$0.0316
  6. Q4 FY25: reported -$0.02 per share against an estimate of -$0.0357
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0306
  8. Q2 FY26: reported -$0.03 per share against an estimate of -$0.0204

ABUS news

  • Press releaseGlobe Newswire

    Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

  • Press releaseGlobe Newswire

    Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Vandana Singh

    Why Is Arbutus Biopharma Stock Gaining Friday?

  • Vandana Singh

    Europe Clears First Flu/COVID Combo Shot From Moderna

  • Press releaseGlobe Newswire

    Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

  • Press releaseGlobe Newswire

    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

  • Press releaseGlobe Newswire

    Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Similar companies

Companies in the same industry as Arbutus Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.